PT  - JOURNAL ARTICLE
AU  - Helfgott, David C.
AU  - Racine-Brzostek, Sabrina
AU  - Short, Kelsey J.
AU  - Zhao, Zhen
AU  - Christos, Paul
AU  - Nino, Itzel
AU  - Niu, Tina
AU  - Contreras, Jorge
AU  - Ritchie, Ellen K.
AU  - Desai, Pinkal
AU  - Samuel, Michael
AU  - Roboz, Gail J.
TI  - Immunogenicity of COVID-19 mRNA Vaccines in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome
AID  - 10.1101/2022.01.26.22269932
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.01.26.22269932
4099  - http://medrxiv.org/content/early/2022/01/28/2022.01.26.22269932.short
4100  - http://medrxiv.org/content/early/2022/01/28/2022.01.26.22269932.full
AB  - Immunocompromised patients are particularly susceptible to serious complications from infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Two mRNA vaccines, BNT162b2 and mRNA-1273, have been shown to have excellent clinical efficacy in immunocompetent adults, but diminished activity in immunocompromised patients. In this study, we measured anti-spike SARS-CoV-2 antibody response, avidity, and surrogate neutralizing antibody activity in Coronavirus Disease 2019 (COVID-19) vaccinated patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Anti-spike SARS-CoV-2 antibody was present in 89% of AML and 88% of MDS patients, but median antibody levels for were lower than in healthy controls (p=0.001 and p=0.04, respectively). SARS-CoV-2 antibody avidity and neutralizing antibody activity from AML patients were significantly lower than controls (p=0.028 and p=0.002, respectively). There was a trend toward higher anti-spike SARS-CoV-2 antibody levels after mRNA-1273 vaccination. Antibody avidity was greater in patients after mRNA-1273 versus BNT162b2 (p=0.01) and there was a trend toward greater neutralizing antibody activity after mRNA-1273 versus BNT162b2 vaccination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Leukemia Fighters fund at New York Presbyterian Hospital and also Dr. Paul Christos was partially supported by the following grant: Clinical and Translational Science Center at Weill Cornell Medical College (1-UL1-TR002384-01).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was approved by the Weill Cornell Medicine Institutional Review Board, IRB#s 21-02023288, 20-11022929I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors